The KEY-NOTE-024 clinical trial [6], conducted in patients with metastatic NSCLC and high PD-L1 expression levels (≥50%), showed the best results reported to date in terms of response rate, progression-free survival (PFS) and overall survival (OS). The gene discussed is CD274; the disease is non-small cell lung carcinoma.